Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

At the end of 2024, as interest rates and inflation were dropping, private equity dry powder was piling up and a new president who many thought would be business-friendly was preparing to return to ...

Major IT companies and solution providers looking to expand their technology portfolios—with AI frequently a driving factor—accounted for many of the biggest acquisitions this year. Here’s a look at ...

Nathan Reiff has been writing expert articles and news about financial topics such as investing and trading, cryptocurrency, ETFs, and alternative investments on Investopedia since 2016. skynesher / ...

Following a mercurial couple of years for biopharma M&A activity, 2025 saw a marked return to form, with a bevy of looming patent expirations and a thawing of the biotech investment scene prompting ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion. In a flurry of activity over the last 12 days of the month, biopharma companies pulled off seven transactions each ...

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. While the year saw an overall ...

Holcim remains a high-quality, well-run cement leader, but trades at a 65%+ premium to its 5-year average P/E. The recent majority acquisition of Cementos Pacasmayo expands LATAM exposure, adds $630M ...

The total number of Canadian M&A deals declined in the second quarter of 2025 as tariff disruption and uncertainty hampered dealmaking activity. However, the overall value of announced Canadian deals ...